Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by WalkOverTheStrton Mar 24, 2021 8:47am
131 Views
Post# 32865007

RE:RE:RE:NASDAQ

RE:RE:RE:NASDAQWithout partnership PRs how is the stock going to get to $6+. A PH3 IND... not likely. 
I think a lot on this board are missing the fact that this exchange is holding the stock back. This stock appears to be easily controlled with a small amount of capital and the recent offering has likely crated even more shorts (hedging play). Without real buy side base IMO you can wish all you want but without a real base of instiutions that can buy we are stuck here... what more would an investor need to wade into Antibe? Only aspect is the holding co and even then the recent offering shows this isn't much of a concern. There is not sufficient capital / instituions wanting in and that is b/c there isnt a suffcient base of them that can b/c we are on this backwater exchange. 

"share price climbing and somewhere between $6 and $15 is likely where they should pull the trigger on the NASDAQ .."
<< Previous
Bullboard Posts
Next >>